Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single-arm Clinical Study of PD-1 Antibody and Bevacizumab in the Treatment of Relapsed or Refractory High-risk Gestational Trophoblasitc Neoplasia After Second-line or Above Combined Chemotherapy

NCT04812002 is registered in ClinicalTrials.gov with Women's Hospital School Of Medicine Zhejiang University as lead sponsor.

NCT NCT04812002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04812002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single-arm Clinical Study of PD-1 Antibody and Bevacizumab in the Treatment of Relapsed or Refractory High-risk Gestational Trophoblasitc Neoplasia After Second-line or Above Combined Chemotherapy
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Phase
Phase 2
Overall status
Unknown status
Start date
April 15, 2021
Completion date
April 15, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gestational trophoblastic neoplasia